Clinical Trials Logo

Prader-Willi Syndrome clinical trials

View clinical trials related to Prader-Willi Syndrome.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05387798 Withdrawn - Clinical trials for Prader-Willi Syndrome

A Phase 3 Extension Study of RAD011 (Cannabidiol Oral Solution) in Patients With Prader-Willi Syndrome

Start date: January 2023
Phase: Phase 3
Study type: Interventional

This is a Phase 3 open-label extension (OLE) study in patients diagnosed with Prader-Willi Syndrome (PWS) who completed the Maintenance Period of the randomized, placebo-controlled Phase 2/3 study SCOUT-015. The primary objective of this study is to assess the long-term safety and tolerability of RAD011.

NCT ID: NCT05198362 Withdrawn - Clinical trials for Prader-Willi Syndrome

Study of Tesomet With Open-label Extension in Subjects With Prader-Willi Syndrome

PWS
Start date: December 28, 2021
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of Tesomet (tesofensine + metoprolol) in subjects with PWS.

NCT ID: NCT04396470 Withdrawn - Clinical trials for Prader-Willi Syndrome

tVNS in Children With Prader-Willi Syndrome

Start date: July 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the current project is to test the impact of transcutaneous vagus nerve stimulation (tVNS) on social ability in children with Prader-Willi Syndrome (PWS). Social ability and blood neuropeptides associated with social functioning will be measured before and after engagement in 12 weeks of tVNS therapy.

NCT ID: NCT04086810 Withdrawn - Clinical trials for Prader-Willi Syndrome

An Open-Label Study of DCCR Tablet in Patients With PWS

Start date: October 2019
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to monitor the long-term safety of DCCR in PWS patients.

NCT ID: NCT04066088 Withdrawn - Clinical trials for Prader-Willi Syndrome

Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi Syndrome

Start date: December 1, 2019
Phase: Phase 4
Study type: Interventional

This is a placebo-controlled clinical trial to assess the utility of Guanfacine Extended Release (GXR) in the management of patients with Prader Willi Syndrome (PWS) who have significant aggression or self-injury. The purpose of this trial is to establish the safety of GXR with a specific focus on metabolic effects.